Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $449.4 million.

  • Ocular Therapeutix's Cash from Financing Activities rose 985736.76% to $449.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $561.7 million, marking a year-over-year increase of 6913.7%. This contributed to the annual value of $561.7 million for FY2025, which is 6913.7% up from last year.
  • According to the latest figures from Q4 2025, Ocular Therapeutix's Cash from Financing Activities is $449.4 million, which was up 985736.76% from $10.4 million recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Cash from Financing Activities ranged from a high of $449.4 million in Q4 2025 and a low of -$1.2 million during Q1 2021
  • For the 5-year period, Ocular Therapeutix's Cash from Financing Activities averaged around $53.4 million, with its median value being $3.4 million (2021).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 10906.54% in 2021, then surged by 41172435.9% in 2024.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Cash from Financing Activities stood at $667000.0 in 2021, then plummeted by 31.33% to $458000.0 in 2022, then skyrocketed by 23517.9% to $108.2 million in 2023, then plummeted by 95.83% to $4.5 million in 2024, then surged by 9857.37% to $449.4 million in 2025.
  • Its Cash from Financing Activities was $449.4 million in Q4 2025, compared to $10.4 million in Q3 2025 and $97.8 million in Q2 2025.